首页> 外文期刊>Journal of glaucoma >The Effects of Remifentanil and Esmolol on Increase in Intraocular Pressure Due to Laryngoscopy and Tracheal Intubation: A Double-Blind, Randomized Clinical Trial
【24h】

The Effects of Remifentanil and Esmolol on Increase in Intraocular Pressure Due to Laryngoscopy and Tracheal Intubation: A Double-Blind, Randomized Clinical Trial

机译:瑞芬太尼和艾司洛尔对喉镜和气管插管引起的眼内压升高的影响:一项双盲,随机临床试验

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose:This study aimed to compare the effects of remifentanil and esmolol on the elevation of intraocular pressure (IOP) and hemodynamic response.Methods:After approval of the institutional Ethics Committee and obtaining informed consent, 60 adult patients with American Society of Anesthesiologists I-II status undergoing elective, nonophthalmic surgery were included in the study. Exclusion criteria were preexisting eye disease, neuromuscular disease, esophageal reflux, hiatus hernia, allergy to any of the study drugs, and the use of -blockers, diuretics, or other antihypertensive agents. The patients were randomized into 2 groups by using the sealed-envelope method, as follows: group E (esmolol) and group R (remifentanil). A single intravenous dose of esmolol (0.5 mg/kg) or remifentanil (1 g/kg) just before induction agents were given to patients in groups E and R, respectively. IOP, heart rate (HR), and mean arterial pressure (MAP) values were recorded before intubation and at 1, 3, 5, and 10 minutes after intubation.Results:The IOP decrease in group R was statistically significant compared with group E (P<0.01). HR values at 10 minutes after intubation were significantly decreased in group E compared with group R (P<0.05). There was no significant difference in MAP values between the groups.Conclusions:It was concluded that remifentanil is more effective than esmolol in preventing IOP elevation related to laryngoscopy and tracheal intubation, while there is no significant difference between the 2 agents in terms of HR and MAP.
机译:目的:本研究旨在比较瑞芬太尼和艾司洛尔对眼内压(IOP)升高和血流动力学反应的影响。方法:经机构伦理委员会批准并获得知情同意后,美国麻醉医师学会I-该研究包括接受择期,非眼科手术的II期状态。排除标准为预先存在的眼部疾病,神经肌肉疾病,食道反流,裂孔疝,对任何一种研究药物过敏,以及使用-阻滞剂,利尿剂或其他降压药。采用密封信封法将患者随机分为2组:E组(艾司洛尔)和R组(瑞芬太尼)。分别在E组和R组中的患者接受诱导剂之前,单次静脉注射艾司洛尔(0.5 mg / kg)或瑞芬太尼(1 g / kg)。插管前和插管后1、3、5和10分钟记录IOP,心率(HR)和平均动脉压(MAP)值。结果:与E组相比,R组的IOP降低具有统计学意义( P <0.01)。与R组相比,E组在插管后10分钟的HR值显着降低(P <0.05)。结论:瑞芬太尼在预防与喉镜和气管插管相关的眼压升高方面比艾司洛尔更有效,而两种药物在心率和心率方面无显着差异。地图。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号